FDA 483 - GRUNENTHAL GMBH - July 10, 2026

GRUNENTHAL GMBH, a bulk drug manufacturer in Germany, was cited during an FDA inspection for a quality control deficiency. The firm's Finished Bulk Product laboratory lacked a formal "rounding" document, which resulted in inconsistent analytical results for product purity. This issue highlights a potential weakness in their laboratory data integrity and procedural controls.